Analyze Your Search

Hints:

  • Action links for each search result record
    • Bookmark: Allows you to Bookmark the page for easy future retrieval 
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • Previous Versions: Only shown if essentially the same document has been republished
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Follow" button to the right of the search box. 
Latest Clinical Trials In Dermatology
  Follow Topic   Edit Search
Your search returned 36 results
from the time period: last 30 days.
Sort by Relevance / Date Group By Source / No Grouping
ClinicalTrials.gov
The Effect of Vitamin D Supplementation on Psoriasis Severity - Full Text View Primary Outcome Measures: Secondary Outcome Measures: Physician Global Assessment (PGA) score [ Time Frame: Baseline and 4 months ] The difference in change between the vitamin D and placebo group in psoriasis severity measured by PGA score. Dermatology Quality of Life Index (DLQI) score [ Time Frame: Baseline, 8 weeks and 4 months ] The difference in change between the vitamin D and placebo group in self-reported
Dermatology (17), Anti-Obesity and Weight Loss (2)
Psoriasis (16), Skin Diseases (1)
ClinicalTrials.gov
A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis - Full Text View The primary objective is to demonstrate added benefit of brodalumab versus a selected systemic comparator in treatment of moderate to severe plaque psoriasis in Germany in subjects who have not previously received systemic treatment for psoriasis.
Dermatology (13)
Psoriasis (11), Skin Diseases (1)
3. AGN-242428 in the Treatment of Plaque Psoriasis  
Date: 11/10/2017 12:00
ClinicalTrials.gov
AGN-242428 in the Treatment of Plaque Psoriasis - Full Text View Primary Outcome Measures: The percentage of participants achieving a reduction (improvement) in Psoriasis Area and Severity Index (PASI) score of ≥ 75% from baseline to Week 16 [ Time Frame: Baseline to Week 16 ] The PASI score ranges from 0-72 (with a higher score indicating greater severity of psoriasis), based on a combination of the severity (erythema, induration, and desquamation) of psoriasis and percentage of affected area.
Dermatology (11)
Psoriasis (11), Erythema (3)
ClinicalTrials.gov
A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab - Full Text View Number of Participants With Swelling of Joints at Baseline [ Time Frame: Baseline (Week 0) ] Participants with swollen 28-joints or 66/68-joints counts according to the practices will be evaluated.
Dermatology (8), Muscular and Skeletal Diseases (6), Immune System Diseases (5)
Psoriasis (8), Psoriatic Arthritis (5), Arthralgia (4)
ClinicalTrials.gov
A Study on the Use of Laser Therapy to Treat Acne Vulgaris - Full Text View Primary Outcome Measures: Safety Assessment [ Time Frame: 14 months ] Evaluation of change in erythema, dryness/excessive scaling, itching, stinging/burning sensation, blistering, and pigmentary changes (hyperpigmentation/ hypopigmentation). Each variable is rated on a scale of increasing severity from 0 to 3.
Dermatology (9), Cardiovascular Diseases (1), Ophthalmology (1)
Acne Vulgaris (8), Pruritus (1), Neoplasms (1)
ClinicalTrials.gov
Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases - Full Text View Primary Outcome Measures: Change from baseline in EuroQoL-5 Dimension (EQ-5D) index score up to Week 24 [ Time Frame: From Week 0 to Week 24 ] The European quality of life-5 dimensions (EQ-5D) is a simple, easy to administer, standardized and self-report instrument for health status, which is applicable to a wide range of health conditions and treatment.
Dermatology (7), Immune System Diseases (4)
Psoriasis (5), Ankylosing Spondylitis (5), Rheumatoid Arthritis (4)
ClinicalTrials.gov
Study of Baricitinib (LY3009104) in Adults With Moderate to Severe Atopic Dermatitis - Full Text View Primary Outcome Measures: Secondary Outcome Measures: Proportion of Participants Achieving IGA of 0 or 1 with a ≥ 2 Point Improvement (Mid or Low Dose) [ Time Frame: 16 Weeks ] Proportion of participants achieving IGA of 0 or 1 with a ≥ 2 point improvement Proportion of Participants Achieving Eczema Area and Severity Index 75 (EASI75) [ Time Frame: 16 Weeks ] Proportion
Dermatology (7), Infectious Diseases (2), Neuroscience (1)
Atopic Dermatitis (6), Infections (2), Eczema (2)
ClinicalTrials.gov
Randomized Double-blind Study on the Benefit of Spironolactone for Treating Acne of Adult Woman. - Full Text View Acne vulgaris of adult woman has increased over the past 10 years; it affects currently 20% to 30% of adult women. The physiopathology of adult woman acne is distinguished from the teenager one by essentially 2 factors: hormonal factor with a peripheral hyperandrogenism coupled with an hypersensibility of cutaneous androgens receptors of these women.
Dermatology (6), Infectious Diseases (1)
Acne Vulgaris (6), 46,XX Gonadal Dysgenesis (2), Phlebitis (1)
ClinicalTrials.gov
Patient Centered Care Situation and Health-related Quality of Life by Patients With Psoriasis, Urticaria or Lupus - Full Text View Psoriasis, HRQL Patients with a medical diagnosis of Psoriasis were enclosed. Behavioral: HRQL Intervention of patient centered care situation and health-related quality of life of patients with Psoriasis, Urticaria or Lupus erythematodes from non-urban practices vs urban practises.
Dermatology (5), Immune System Diseases (3)
Psoriasis (5), Urticaria (3)
ClinicalTrials.gov
An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis. - Full Text View Primary Outcome Measures: Secondary Outcome Measures: Proportion of subjects achieving minimal disease activity (MDA). [ Time Frame: At each visit through Week 148. ] To assess the effect of filogotinib on MDA in PsA patients. Proportion of subjects achieving ACR20 response.
Muscular and Skeletal Diseases (5), Dermatology (5)
Psoriasis (5), Psoriatic Arthritis (4), Pruritus (3)
1 2 3 4  | Next Page»